CRSP · CRISPR Therapeutics AG
$58.12
-1.69 (-2.83%)
At close · Aug 20
Market Cap
$5.48B
Shares
96.69M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$58.12
Open$58.73
Day$56.94–60.90
52W close$44.34–76.78
Avg vol 30d1.6M
Short int18.8M · 19.5% float · 11.5d
Short vol59%
DataJan 2020–Aug 2026
Filing10-Q · Aug 3
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 3, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Neutral
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+9%
above
Price vs 50-day avg
+11%
above
RSI (14)
64
neutral
MACD trend
Positive
52-week position
42%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+22%
trailing
6-month return
−3%
trailing
YTD return
+11%
this year
Relative strength
−15%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $53 › 200d $53 — 200d above 50d
Institutional flow
Accumulating
+5% holders QoQ · +81 funds added
Insider flow
Distributing
Net -$210.6K over 90 days · 100% sells
Short interest
Falling
19.46% of float · ▼ -5.0% MoM · 11.5 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
524 holders — near 3-yr high, broad support
Squeeze score
83
high risk · 0–100
Fundamentals
Revenue growth
+9170%
Y/Y
EPS growth
−49%
Y/Y
Free cash flow
$-345.9M
Balance sheet
$347.6M
net cash
Quant / Vol
risk profile
Volatility
60%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
4.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Prior guidance
period ended
· from the 8-K filed Nov 10, 2025
Total CASGEVY revenue
· this year
at least $100M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+9%
Bullish
Price vs 50-day avg
+11%
Bullish
RSI (14)
64
Neutral
MACD trend
Positive
Bullish
52-week position
42%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $53 › 200d $53 — 200d above 50d
Institutional flow
Accumulating
+5% holders QoQ · +81 funds added
Insider flow
Distributing
Net -$210.6K over 90 days · 100% sells
Short interest
Falling
19.46% of float · ▼ -5.0% MoM · 11.5 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
524 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $44
Now $58 · 42%
Range high $77
vs 200-day avg +9%
vs 50-day avg +11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| patients with SCD or TDT may be eligible for treatment with CASGEVY for the first time | 5,500 | second quarter of 2026 | — |
| people who have initiated the CASGEVY treatment journey | 500 | first quarter 2026 | — |
| patients received infusions of CASGEVY | 64 | full year 2025 | — |
| people with SCD or TDT initiated the treatment process with their first cell collection | 147 | full year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRSP
this stock
CRISPR Therapeutics AG
|
$5.48B | +10.8% | +9169.8% | — | 19.5% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRSP | +7.7% | +22.3% | -3.4% | +21.1% | +10.8% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +9.6% | +19.0% | -14.5% | +19.0% | -1.0% |
Key facts
CIK
1674416
CUSIP
H17182108
13F (30d)
463 filings
455 filers
Visit website
Investor relations